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http://www.biomedcentral.com/1471-2369/14/126RESEARCH ARTICLE Open AccessHaplotype association analysis of genes within
the WNT signalling pathways in diabetic
nephropathy
David H Kavanagh1, David A Savage2, Christopher C Patterson1, Amy Jayne McKnight1, John K Crean3,
Alexander P Maxwell1, Gareth J McKay1* and the Warren 3/UK GoKinD Study GroupAbstract
Background: Renal interstitial fibrosis and glomerular sclerosis are hallmarks of diabetic nephropathy (DN)
and several studies have implicated members of the WNT pathways in these pathological processes. This study
comprehensively examined common genetic variation within the WNT pathway for association with DN.
Methods: Genes within the WNT pathways were selected on the basis of nominal significance and consistent
direction of effect in the GENIE meta-analysis dataset. Common SNPs and common haplotypes were examined
within the selected WNT pathway genes in a white population with type 1 diabetes, discordant for DN (cases:
n = 718; controls: n = 749). SNPs were genotyped using Sequenom or Taqman assays. Association analyses were
performed using PLINK, to compare allele and haplotype frequencies in cases and controls. Correction for multiple
testing was performed by either permutation testing or using false discovery rate.
Results: A logistic regression model including collection centre, duration of diabetes, and average HbA1c as
covariates highlighted three SNPs in GSK3B (rs17810235, rs17471, rs334543), two in DAAM1 (rs1253192, rs1252906)
and one in NFAT5 (rs17297207) as being significantly (P < 0.05) associated with DN, however these SNPs did not
remain significant after correction for multiple testing. Logistic regression of haplotypes, with ESRD as the outcome,
and pairwise interaction analyses did not yield any significant results after correction for multiple testing.
Conclusions: These results indicate that both common SNPs and common haplotypes of WNT pathway genes are
not strongly associated with DN. However, this does not completely exclude these or the WNT pathways from
association with DN, as unidentified rare genetic or copy number variants could still contribute towards the genetic
architecture of DN.
Keywords: Diabetic nephropathy, WNT signalling pathway, Association study, End-stage renal diseaseBackground
Diabetic nephropathy (DN) is a microvascular complica-
tion of diabetes and is the most frequent cause of end-
stage renal disease (ESRD) in western populations [1].
Renal interstitial fibrosis and glomerular sclerosis are
histological hallmarks of DN and several studies have
implicated members of the WNT pathways in these
pathological processes [2-9].* Correspondence: g.j.mckay@qub.ac.uk
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Commons Attribution License (http://creativec
reproduction in any medium, provided the orThe WNT pathways can be subdivided into canoni-
cal β-catenin dependent and non-canonical β-catenin
independent pathways (Figure 1). Canonical WNT signal-
ling is central to numerous developmental processes and
variants discovered within members of this pathway have
been implicated in multiple complex diseases such as
familial adenomatous polyposis coli, colorectal and hepa-
tocellular cancers, type 2 diabetes and schizophrenia
[10-14]. Non-canonical WNT signalling is less well de-
fined, in part due to further subdivisions into the WNT/
Ca2+ and the WNT planar cell polarity pathways. These
pathways have been shown to modulate cytoskeletal
reorganisation and activation of the JNK and MAPKral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Wnt signalling pathways implicated in diabetic nephropathy. Eleven genes encoding members of the Wnt signalling pathway
were prioritized for assessment of association with diabetic nephropathy (AXIN1, CALM3, CTNNB1, DAAM1, DKK2, GSK3B, NFAT5, WNT3, WNT5A,
WNT6 and WNT16). (A) Canonical WNT signalling: Some WNT ligands bind to FZD and LRP receptors. DKK internalises the LRP receptors blocking
canonical WNT signalling. DVL recruits the AXIN GSK3B destruction complex that is responsible for marking B-catenin for proteosomal
degradation. (B) Non-canonical WNT signalling: Certain WNT ligands bind to FZD receptors and elicit the activation of DVL and heterotrimeric
G-proteins which in turn can activate DAAM which regulates cytoskeletal organization and focal adhesion dynamics. In addition, activation of
CALM regulates the transcription factor NFAT and modulates gene expression.
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motility and adherence of the mesangial cell, perturbing
the cell's response to dynamic mechanical forces, which is
the key function of the mesangial cell.
In vitro epithelial-to-mesenchymal transition (EMT)
promotes renal fibrosis and can be induced by TGF-β1
[18], an integrin-linked kinase. Both the canonical WNT
pathway and TGF-β1 require activation of β-catenin, in
addition to the E-cadherin/β-catenin complexes localised
to epithelial intercellular junctions, implicating both
β-catenin and the WNT pathway in the regulation of the
EMT [19]. Furthermore, GSK3B, the protein responsible
for phosphorylation of the β-catenin molecule and its
subsequent proteosomal degradation, has been shown to
prevent transition to a mesenchymal phenotype in hu-
man embryonic stem cells [20]. Several WNT ligands,
FZD receptors and β-catenin have all been reported to
be differentially expressed in the unilateral ureteral
obstructed (UUO) mouse model of renal injury [4]. In
addition, Dickkopf-1 (DKK1), a WNT signalling anta-
gonist, was shown to promote hyperglycaemia-induced
mesangial matrix expansion in rat mesangial cells [5].
Previously, common variants within four key genes in
the WNT pathway have been investigated for association
with diabetic nephropathy [21]. In the present study, a
more comprehensive assessment was undertaken of com-
mon variants in multiple genes within the WNT pathway.Due to the large number of WNT pathway genes (>65),
eight potential candidate genes were chosen on the basis
of single nucleotide polymorphisms (SNPs) reaching a
nominal significance threshold of 0.05 from the meta-
analysed Genetics of Nephropathy–an International Effort
(GENIE) Consortium dataset (Table 1) [22]. The chosen
SNPs also showed a consistent direction of effect in each
of the three case–control collections represented by
the GENIE Consortium meta-analysed dataset, an inter-
national collaboration of three cohorts of type 1 diabetic
patients discordant for DN totalling 2916 with nephropa-
thy and 3315 without nephropathy [22]. Three additional
genes, CTNNB1, WNT5A and WNT6, were also included
within the analysis despite failing to meet the inclusion
criteria, on the basis of previous suggestion of their
involvement in the pathogenesis of DN. Although the
genotyping platforms used to determine the GENIE data
provided reasonable coverage across the potential genes of
interest, additional informative haplotype tagging SNPs
identified through CEU participant data from HapMap
offers a more comprehensive evaluation of any potential
genetic effect.
Methods
Participants
Research ethics approval was obtained from the South
and West Multicentre Research Ethics Committee
Table 1 Genes included within the analysis on the basis of significant association (P < 0.05) within the GENIE
meta-analysis [22] and demonstrating a consistent direction of effect across all four cohorts
Chromosome Position Gene SNP Direction Allele P-value
2 219395841 WNT6 rs6436094 - + ?? A 0.19
2 219411542 WNT6 rs730947 - + −+ A 0.12
2 219427976 WNT6 rs7596898 ?-?? T 0.73
2 219428221 WNT6 rs940469 + − ++ T 0.11
2 219429434 WNT6 rs11695967 + − ++ T 0.11
2 219434742 WNT6 rs10193725 - + −− T 0.18
2 219440386 WNT6 rs6754599 - + −+ C 0.36
2 219452118 WNT6 rs3806557 +−−- A 0.95
2 219454805 WNT6 rs10177996 -+++ T 0.95
2 219458990 WNT6 rs2385199 -+++ A 0.94
2 219464627 WNT6 rs7349332 ++−− T 0.61
3 41205327 CTNNB1 rs2691678 – + − A 0.32
3 41205658 CTNNB1 rs7630377 – + − T 0.58
3 41209520 CTNNB1 rs9859392 ++ − + C 0.39
3 41215181 CTNNB1 rs3864004 —— A 0.38
3 41218746 CTNNB1 rs3915129 ++++ T 0.38
3 41229650 CTNNB1 rs2140090 —— T 0.38
3 41236983 CTNNB1 rs1798802 – + − A 0.59
3 41237448 CTNNB1 rs13072632 ++++ T 0.38
3 41243358 CTNNB1 rs11564447 + − +− T 0.41
3 41247085 CTNNB1 rs1880481 —— A 0.37
3 41249076 CTNNB1 rs11564450 ++++ C 0.37
3 41254444 CTNNB1 rs4135385 +−−+ A 0.48
3 41259540 CTNNB1 rs9883073 – + − A 0.41
3 41262022 CTNNB1 rs11711946 ++ − + T 0.41
3 41270771 CTNNB1 rs11129896 ++++ T 0.20
3 55450313 WNT5A rs815533 -++− A 0.73
3 55456115 WNT5A rs3913369 - + −− T 0.10
3 55462468 WNT5A rs751194 – + − A 0.15
3 55464838 WNT5A rs1499890 – + − A 0.15
3 55466053 WNT5A rs629537 +−−- A 0.82
3 55466476 WNT5A rs503022 +−−- A 0.76
3 55467366 WNT5A rs645486 + − +− A 0.46
3 55468554 WNT5A rs476986 –++ A 0.47
3 55469119 WNT5A rs6792802 – + − T 0.07
3 55471300 WNT5A rs11706227 + − ++ T 0.07
3 55472993 WNT5A rs11710229 - + −− A 0.06
3 55474704 WNT5A rs12497254 – + − A 0.08
3 55475448 WNT5A rs10865994 – + − A 0.07
3 55476215 WNT5A rs1829556 ++ − + T 0.08
3 55482321 WNT5A rs556874 -++− T 0.13
3 55486715 WNT5A rs472631 +−−- A 0.73
3 55494897 WNT5A rs648872 + − ++ A 0.77
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Table 1 Genes included within the analysis on the basis of significant association (P < 0.05) within the GENIE
meta-analysis [22] and demonstrating a consistent direction of effect across all four cohorts (Continued)
3 55495818 WNT5A rs566926 + − ++ T 0.59
3 55506307 WNT5A rs557077 +−−- A 0.63
3 55506999 WNT5A rs1160047 —+ A 0.39
3 121176301 GSK3B rs6771023 ++++ T 0.05
3 121225411 GSK3B rs6770314 —— A 0.04
3 121232101 GSK3B rs9851174 —— A 0.04
3 121246776 GSK3B rs7652172 —— T 0.04
3 121255730 GSK3B rs968824 ++++ A 0.04
3 121273402 GSK3B rs334536 ++++ A 0.05
3 121274994 GSK3B rs334535 —— T 0.05
3 121292295 GSK3B rs334559 —— A 0.05
4 108110470 DKK2 rs17509845 ++++ A 0.01
7 120715028 WNT16 rs2952556 —— A <0.01
7 120723242 WNT16 rs10241888 —— A <0.01
7 120727672 WNT16 rs2707521 —— T 0.01
7 120732453 WNT16 rs1547960 ++++ A <0.01
7 120739818 WNT16 rs10231005 —— A <0.01
14 58700292 DAAM1 rs6573249 —— T 0.04
14 58728544 DAAM1 rs1252906 ++++ A 0.02
14 58735687 DAAM1 rs8016570 ++++ T 0.03
14 58744616 DAAM1 rs2146009 ++++ A 0.01
14 58748939 DAAM1 rs1252989 ++++ A 0.01
14 58753987 DAAM1 rs1270988 ++++ A 0.01
14 58795556 DAAM1 rs17095967 ++++ A 0.02
14 58800998 DAAM1 rs1253005 —— T 0.04
14 58847352 DAAM1 rs7149497 —— A 0.02
14 58870553 DAAM1 rs1957409 —— A 0.03
16 312598 AXIN1 rs3916990 ++++ A 0.03
16 68144622 NFAT5 rs17230557 ++++ T 0.02
16 68184592 NFAT5 rs17231138 ++++ A 0.01
16 68198345 NFAT5 rs17297088 —— T 0.02
16 68200854 NFAT5 rs17297207 ++++ A 0.02
16 68207765 NFAT5 rs17231474 ++++ A 0.02
16 68224440 NFAT5 rs6499238 —— T 0.02
16 68262239 NFAT5 rs1437137 —— A 0.02
16 68309874 NFAT5 rs689453 —— T 0.02
17 42221887 WNT3 rs199496 ++++ A 0.01
17 42223260 WNT3 rs11655598 ++++ C 0.05
17 42223596 WNT3 rs199495 —— A 0.02
17 42229159 WNT3 rs11650531 ++++ T 0.04
19 51811750 CALM3 rs11083840 ++++ T 0.03
Direction of effect represents that observed in the FinnDiane, UK-ROI, US GoKinD George Washington University, US GoKinD Joslin Diabetes Center.? signifies
where a marker failed QC in the original collection and was therefore unavailable for meta-analysis.
The P value presented represents the association of the meta-analysed data from all four GENIE cohorts.
Kavanagh et al. BMC Nephrology 2013, 14:126 Page 4 of 10
http://www.biomedcentral.com/1471-2369/14/126
Kavanagh et al. BMC Nephrology 2013, 14:126 Page 5 of 10
http://www.biomedcentral.com/1471-2369/14/126(MREC/98/6/71) and Queens University Belfast Research
Ethics Committee, and written informed consent obtained
prior to participation. All recruited individuals were white,
had type 1 diabetes mellitus (T1D) diagnosed before 32
years of age and were born in the UK or Ireland. Cases
with nephropathy (n = 718) and controls without nephro-
pathy (n = 749) were from the Warren 3/UK Genetics of
Kidneys in Diabetes (GoKinD) and all-Ireland collections
[23]. The definition of DN in cases was based on develop-
ment of persistent proteinuria (>0.5g protein/24h) at least
10 years after diagnosis of T1D, hypertension (blood pres-
sure > 135/85 mmHg or treatment with antihypertensive
agents) and associated diabetic retinopathy. Controls were
individuals with T1D for at least 15 years with normal
urinary albumin excretion rates and no evidence of
microalbuminuria on repeated testing (at least 3 assays
measuring albumin excretion over a minimum 12 month
period, with each test separated by at least 3 months). In
addition, control subjects had not been prescribed antihy-
pertensive drug treatment avoiding possible misclassifica-
tion of diabetic individuals with nephropathy as ‘control
phenotypes’ when the use of antihypertensive treatment
may have reduced urinary albumin excretion into the nor-
mal range. Individuals with micro-albuminuria were ex-
cluded from both case and control groups since it is not
possible to confidently assign a case or control status to
such individuals as their urinary albumin excretion may
either regress or progress over time [24].
Haplotype definition, SNP selection and genotyping
A total of 11 genes (AXIN1, CALM3, CTNNB1, DAAM1,
DKK2, GSK3B, NFAT5, WNT3, WNT5A, WNT6 and
WNT16) were chosen for genotyping (Table 1). SNPs were
selected from within these 11 genes to tag common haplo-
types (>5% frequency within the HapMap CEU popula-
tion). Haplotypes for each gene investigated were
selected from Phase III, release 2 HapMap (http://www.
hapmap.org) CEPH data (Utah residents with ancestry
in northern and western Europe; CEU) using Haploview
(http://www.broadinstitute.org/haploview) to visualise
common haplotypes. Haplotypes were defined using the
confidence interval method in Haploview as described
in Gabriel et al. [25]. Adjacent haplotypes that had a
multi-allelic D-prime of greater 0.9 were combined in
an iterative fashion. SNPs were selected using multi-
marker tagging for their ability to tag unique haplotypes
with r2 > 0.8 (LOD threshold 3.0). All SNPs had a minor
allele frequency (MAF) ≥5%, with quality control filters
of genotype call rate ≥95%, and no deviation from
Hardy–Weinberg equilibrium (HWE; P < 0.001).
Genotyping was performed by MassARRAY iPLEX
(Sequenom, San Diego, CA, USA) or Taqman 5' nuclease
(Applied Biosystems, Foster City, CA, USA) assays
according to the manufacturers’ instructions. DNA sampleswere excluded if missing genotypes exceeded 10%. Other
quality control measures included parent/offspring trio
samples, duplicates on plates, random sample allocation to
plates, independent scoring of problematic genotypes by
two individuals and re-sequencing of selected DNAs to
validate genotypes.
Statistical analysis
Clinical characteristics of cases and controls were com-
pared using the z-test for large independent samples and
the χ2 test. Association analyses were performed using
PLINK [26]. Initially a χ2 test for trend (1 df ) was used
with adjustment for collection centre. Logistic regression
analysis was then performed on each SNP with terms for
potential confounders (collection centre, gender, du-
ration of T1D and HbA1c) included in the model. The
level of statistical significance was set at 5% with correc-
tion for multiple testing performed by permutation test
(n = 100,000). Pairwise interactions between SNPs were
tested in the statistical programming package R, using
logistic regression to compare models with and without
the interaction terms to obtain a likelihood ratio test.
The results of the interaction analysis were corrected for
multiple testing by false discovery rate (FDR < 5%).
Results and discussion
A total of 90 SNPs were genotyped, 85 using
MassARRAY iPLEX Gold technology (Sequenom, San
Diego, CA, USA), and five using Taqman 5’ nuclease
assay (Applied Biosystems, Foster City, CA, USA) in
719 cases and 748 controls. Quality criteria were applied
to the data before association analysis. A total of 35 in-
dividuals with more than 10% missing genotype data
were removed from the analysis. All SNPs passed the
genotyping and Hardy-Weinberg thresholds of 95% and
P < 0.001 respectively. No Mendelian errors or incon-
sistencies between duplicate samples were observed.
The final average genotyping rate was 98.9% in 700
cases, and 732 controls.
The clinical characteristics of the DN cases (n = 700)
and diabetic controls (n = 732) genotyped in this study,
which met quality control filters, are listed in Table 2.
There were more males, higher mean HbA1c and blood
pressure values (despite the use of antihypertensive
treatment) in the case group compared with the control
group. All comparisons were significant at P < 0.001 with
the exception of age at diagnosis which did not differ
significantly between groups. Approximately one quarter
of cases (26.6%) had ESRD.
SNPs chosen to tag common haplotypes across the 11
genes selected on the basis of their significant and com-
mon direction of effect across the GENIE cohorts (Table 1)
[22] were assessed by logistic regression analysis with ad-
justment for collection centre, gender, duration of T1D
Table 2 Clinical characteristics of the genotyped diabetic
nephropathy (DN) cases and diabetic controls
Characteristic DN Case
(n = 700)
Control
(n = 732)
Male; n (%) 405 (57.8%) 306 (41.8%)
Age at diagnosis of T1D (yr) 14.7 ± 7.6 15.4 ± 7.9
Duration of T1D (yr)a 33 ± 9.3 28.1 ± 9
HbA1c (%)b 9 ± 1.9 8.6 ± 1.5
Systolic blood pressure (mmHg)b 144.9 ± 20.9 125.1 ± 14.8
Diastolic blood pressure (mmHg)b 81.5 ± 11.4 75.5 ± 7.7
Body mass index (kg/m2) 26.3 ± 4.8 26.1 ± 4.2
Serum cholesterol (mmol/L) 5.3 ± 1.2 5.1 ± 0.9
Serum creatinine (umol/L)c; median
(interquartile range)
130 (102–182.5) 92 (78.8 - 105)
Glomerular filtration rate
(ml/min/1.73m2)c; median
(interquartile range)
47.8 (33.6 - 66.2) 70 (59.3 - 85.5)
End-stage renal disease n (%) 186 (26.6%) NA
Unless otherwise stated values are mean ± standard deviation.
aCalculated from the dates of diagnosis and recruitment.
bAverage of the three most recent values prior to recruitment.
cExcludes subjects receiving renal replacement therapy (dialysis or transplant).
P < 0.05 for age at diagnosis; P <0.001 for all other comparisons except body
mass index.
T1D = type 1 diabetes.
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equilibrium (LD) blocks were identified across the 11
genes, yielding 110 common haplotypes with an esti-
mated frequency >5%. None of the haplotypes examined
were significantly associated with DN at P < 0.01, how-
ever eight haplotypes were significantly associated with
DN at P < 0.05. Of the eight haplotypes, three were in
GSK3B, two in AXIN1, two in DAAM1, and one in
NFAT5. However, no significant association between
haplotype and DN remained after correction for mul-
tiple testing (data not shown).
In a single marker analysis, adjusted by collection centre,
no SNPs were associated with DN at P < 0.01 (the signifi-
cance threshold set was corrected for multiple testing),
however five SNPs, rs17810235, rs11639947, rs11646942,
rs17095819, and rs17510191 in GSK3B, NFAT5, AXIN1,
DAAM1, DKK2 had P-values <0.05 as shown in Table 4a.
Logistic regression analyses were performed with adjust-
ment for collection centre, gender, duration of T1D, and
average HbA1c as covariates in the model. The most sig-
nificant association was reported for rs17810235 in
GSK3B (Table 4b; P = 0.006). Five additional SNPs demon-
strated a P <0.05, although they were not supported in the
univariate analysis alone. Although limited in power, a
subgroup analysis defined by comparison of ESRD as the
primary phenotype versus non-ESRD, identified two sig-
nificantly associated SNPs, rs1253192 and rs11079737 in
DAAM1 and WNT3 respectively with P = 0.009, althoughneither association survived correction for multiple testing
(Table 4c).
Assessment of 4005 pair-wise interactions between the
90 SNPs was performed by logistic regression analyses
with adjustment for collection centre, gender, duration of
T1D, and HbA1c. The χ2 likelihood ratio tests (Table 5)
identified four interaction terms as nominally significant
between SNPs in AXIN1, DAAM1, DKK2, WNT3 and
WNT6. However, these interactions were not significant
following correction for multiple testing by FDR P < 5%.
There is an increasing body of evidence to suggest that
modulation of the WNT pathways may play a role in the
development of DN. β-catenin and TCF/LEF have been
shown to directly induce the expression of the cyclic nu-
cleotide phosphodiesterase CNP, a regulator of fibroblast
proliferation and activation [2]. The expression of secreted
frizzled-related protein 4 (SFRP4), an inhibitor of WNT
signalling, is decreased following UUO. This decrease is
concomitant with increased levels of WNT/β-catenin
signalling, in tubular and interstitial cells, along with
increased fibronectin and smooth muscle actin, both
markers of fibrosis. Introduction of recombinant SFRP4
reduced the markers of fibrosis and WNT/β-catenin sig-
nalling. Furthermore E-cadherin expression was partially
maintained by treatment with recombinant SFRP4, and
the number of myofibroblasts decreased [3]. DKK1 is
shown to be increased in mesangial cells in response to
stimulation with high concentrations of glucose [5]. In
addition high concentrations of glucose decreased WNT
signalling and increased TGF-β1 and fibronectin expres-
sion in mesangial cells. Transfection of WNT4, WNT5a,
GSK3β and β-catenin ameliorated the TGF-β1-induced
fibrosis [8]. Cultured podocytes with stabilised β-catenin
are less motile and less adherent to the extracellular
matrix whereas deletion of β-catenin rendered the cells
more susceptible to apoptosis [6].
Gene-based assessments of association are increasingly
been viewed as a useful complement to genome-wide as-
sociation studies (GWAS) [27]. The gene-based approach
reduces the problems associated with multiple testing that
inhibit GWAS by reducing the number of statistical tests
under consideration. Our study has adopted a two stage
approach to evaluate common variants in all WNT path-
way members in relation to DN. SNPs located in genes
implicated in the WNT pathways that failed to demon-
strate significant association and direction of effect across
all GENIE cohorts [22] were excluded at the first step.
WNT pathway members that demonstrated significant as-
sociation and direction of effect with DN across the three
GENIE case–control collections were then evaluated more
meticulously through refined genotyping of haplotype tag-
ging SNPs. This approach offers a more comprehensive
assessment of common variants across the WNT path-
ways in comparison to previously published studies.
Table 3 Minor allele frequencies, genotype counts and logistic regression model adjusted for collection centre, gender,
duration of type 1 diabetes, and average HbA1c
Chra Position Gene SNP ID Allele Case count MAF Control count MAF ORb C.I.c Pd
2 219428221 WNT6 rs940469 [T/C] 24/170/483 0.16 24/170/483 0.18 0.86 0.67 - 1.11 0.25
2 219430908 WNT6 rs690877 [T/C] 56/276/360 0.28 56/276/360 0.27 0.92 0.74 - 1.14 0.43
2 219440386 WNT6 rs6754599 [G/C] 18/166/494 0.15 18/166/494 0.17 0.85 0.65 - 1.11 0.22
2 219458990 WNT6 rs2385199 [G/A] 23/200/471 0.18 23/200/471 0.19 0.90 0.7 - 1.16 0.43
3 41205327 CTNNB1 rs2691678 [C/T] 51/250/390 0.25 51/250/390 0.25 1.01 0.81 - 1.26 0.91
3 41243358 CTNNB1 rs11564447 [G/T] 1/59/634 0.04 1/59/634 0.04 0.91 0.57 - 1.43 0.68
3 41254444 CTNNB1 rs4135385 [G/A] 49/237/398 0.24 49/237/398 0.23 1.04 0.84 - 1.3 0.70
3 55450313 WNT5A rs815533 [A/G] 22/206/466 0.18 22/206/466 0.17 1.27 0.99 - 1.64 0.06
3 55456115 WNT5A rs3913369 [T/G] 33/261/394 0.24 33/261/394 0.23 0.91 0.72 - 1.14 0.40
3 55466053 WNT5A rs629537 [A/G] 11/145/534 0.12 11/145/534 0.13 0.89 0.67 - 1.18 0.40
3 55467090 WNT5A rs845542 [C/T] 44/272/377 0.26 44/272/377 0.25 1.19 0.95 - 1.49 0.13
3 55494897 WNT5A rs648872 [T/C] 13/172/501 0.14 13/172/501 0.17 0.86 0.67 - 1.1 0.22
3 55495818 WNT5A rs566926 [T/G] 49/252/368 0.26 49/252/368 0.27 0.99 0.8 - 1.24 0.96
3 121016036 GSK3B rs11917714 [T/C] 19/205/470 0.18 19/205/470 0.16 1.02 0.79 - 1.31 0.89
3 121018485 GSK3B rs11929668 [G/C] 22/170/501 0.15 22/170/501 0.18 0.87 0.67 - 1.12 0.27
3 121133839 GSK3B rs17204365 [C/T] 2/41/648 0.03 2/41/648 0.03 1.61 0.91 - 2.85 0.10
3 121157741 GSK3B rs17810235 [T/C] 74/303/312 0.33 74/303/312 0.29 1.33 1.09 - 1.64 0.01
3 121300363 GSK3B rs17471 [A/T] 3/110/581 0.08 3/110/581 0.09 0.67 0.47 - 0.95 0.02
3 121306727 GSK3B rs11927974 [A/G] 8/101/584 0.08 8/101/584 0.09 0.98 0.71 - 1.35 0.89
3 121307901 GSK3B rs334538 [A/G] 22/191/481 0.17 22/191/481 0.19 0.89 0.7 - 1.14 0.35
3 121308854 GSK3B rs12053912 [T/A] 17/186/485 0.16 17/186/485 0.14 1.21 0.92 - 1.58 0.18
3 121315311 GSK3B rs334543 [C/A] 66/311/307 0.32 66/311/307 0.35 0.79 0.65 - 0.97 0.02
4 108055760 DKK2 rs429941 [G/A] 53/282/356 0.28 53/282/356 0.28 1.08 0.88 - 1.34 0.46
4 108062942 DKK2 rs10488898 [A/G] 2/77/603 0.06 2/77/603 0.07 0.85 0.58 - 1.24 0.40
4 108065243 DKK2 rs17037102 [A/G] 7/132/526 0.11 7/132/526 0.10 1.17 0.85 - 1.6 0.34
4 108084260 DKK2 rs10488899 [G/T] 42/237/410 0.23 42/237/410 0.21 1.10 0.88 - 1.39 0.40
4 108110470 DKK2 rs17509845 [A/G] 1/66/622 0.05 1/66/622 0.05 1.08 0.69 - 1.7 0.74
4 108120464 DKK2 rs17618172 [G/A] 20/219/445 0.19 20/219/445 0.20 1.01 0.79 - 1.28 0.96
4 108135958 DKK2 rs7690634 [A/T] 9/165/515 0.13 9/165/515 0.12 1.19 0.89 - 1.58 0.24
4 108165736 DKK2 rs4956277 [C/A] 30/246/396 0.23 30/246/396 0.24 0.94 0.75 - 1.17 0.58
4 108170809 DKK2 rs10021344 [G/A] 150/357/185 0.47 150/357/185 0.48 0.99 0.82 - 1.19 0.88
4 108173328 DKK2 rs956137 [A/C] 4/111/577 0.09 4/111/577 0.08 1.28 0.92 - 1.8 0.15
4 108173463 DKK2 rs6827902 [C/A] 28/237/416 0.22 28/237/416 0.21 1.15 0.91 - 1.45 0.23
4 108181414 DKK2 rs6823507 [C/T] 1/88/593 0.07 1/88/593 0.08 0.87 0.6 - 1.26 0.46
4 108185493 DKK2 rs419178 [C/T] 38/272/379 0.25 38/272/379 0.27 0.86 0.69 - 1.07 0.17
4 108199999 DKK2 rs398093 [T/C] 12/138/510 0.12 12/138/510 0.12 1.09 0.81 - 1.46 0.58
4 108200154 DKK2 rs17510191 [C/T] 20/251/423 0.21 20/251/423 0.18 1.13 0.89 - 1.43 0.31
7 120727672 WNT16 rs2707521 [T/C] 103/338/239 0.40 103/338/239 0.41 0.90 0.74 - 1.1 0.32
7 120738146 WNT16 rs13247600 [C/G] 3/81/610 0.06 3/81/610 0.07 1.08 0.74 - 1.57 0.69
7 120738380 WNT16 rs2707520 [G/T] 166/340/183 0.49 166/340/183 0.49 1.12 0.92 - 1.35 0.25
7 120741508 WNT16 rs983926 [A/G] 6/101/587 0.08 6/101/587 0.09 0.93 0.67 - 1.3 0.68
7 120751201 WNT16 rs3757552 [C/T] 9/151/534 0.12 9/151/534 0.12 0.89 0.67 - 1.19 0.44
7 120762001 WNT16 rs3801387 [C/T] 69/283/340 0.30 69/283/340 0.29 1.00 0.81 - 1.23 0.99
Kavanagh et al. BMC Nephrology 2013, 14:126 Page 7 of 10
http://www.biomedcentral.com/1471-2369/14/126
Table 3 Minor allele frequencies, genotype counts and logistic regression model adjusted for collection centre, gender,
duration of type 1 diabetes, and average HbA1c (Continued)
7 120774586 WNT16 rs2707461 [T/C] 18/187/489 0.16 18/187/489 0.17 0.98 0.77 - 1.26 0.89
14 58696138 DAAM1 rs8016068 [T/C] 4/176/514 0.13 4/176/514 0.12 1.09 0.81 - 1.47 0.57
14 58713714 DAAM1 rs17095819 [G/A] 15/185/477 0.16 15/185/477 0.13 1.28 0.96 - 1.71 0.09
14 58728544 DAAM1 rs1252906 [G/T] 19/164/511 0.15 19/164/511 0.18 0.75 0.58 - 0.97 0.03
14 58826755 DAAM1 rs7155987 [T/C] 18/180/496 0.16 18/180/496 0.14 1.10 0.84 - 1.44 0.48
14 58833620 DAAM1 rs12878138 [T/C] 2/99/593 0.07 2/99/593 0.07 0.96 0.67 - 1.39 0.84
14 58861382 DAAM1 rs941882 [C/A] 40/238/416 0.23 40/238/416 0.23 1.03 0.82 - 1.28 0.82
14 58885779 DAAM1 rs17834014 [G/A] 3/86/605 0.07 3/86/605 0.08 0.97 0.67 - 1.42 0.88
14 58886484 DAAM1 rs12880248 [A/G] 12/177/505 0.14 12/177/505 0.14 1.06 0.8 - 1.39 0.70
14 58889427 DAAM1 rs12878070 [G/T] 150/334/210 0.46 150/334/210 0.42 1.10 0.91 - 1.32 0.33
14 58908520 DAAM1 rs17096179 [C/A] 5/104/585 0.08 5/104/585 0.09 0.88 0.63 - 1.24 0.47
14 58913159 DAAM1 rs1253192 [A/G] 5/80/609 0.06 5/80/609 0.09 0.65 0.46 - 0.93 0.02
16 275374 AXIN1 rs2685127 [T/C] 7/157/529 0.12 7/157/529 0.13 1.02 0.76 - 1.36 0.92
16 276397 AXIN1 rs400037 [T/C] 32/243/410 0.22 32/243/410 0.22 0.97 0.77 - 1.21 0.77
16 281080 AXIN1 rs12925669 [A/G] 22/171/501 0.15 22/171/501 0.16 1.06 0.82 - 1.37 0.65
16 289294 AXIN1 rs214246 [C/T] 148/349/196 0.47 148/349/196 0.49 0.93 0.77 - 1.12 0.45
16 303385 AXIN1 rs12930863 [C/T] 20/175/490 0.16 20/175/490 0.16 1.05 0.81 - 1.36 0.70
16 313818 AXIN1 rs11646942 [A/C] 51/261/355 0.27 51/261/355 0.31 0.89 0.72 - 1.1 0.29
16 333343 AXIN1 rs395901 [A/G] 7/115/569 0.09 7/115/569 0.09 0.82 0.6 - 1.14 0.24
16 336265 AXIN1 rs1805105 [A/G] 67/310/284 0.34 67/310/284 0.31 1.19 0.97 - 1.47 0.10
16 68112382 NFAT5 rs12921716 [A/G] 6/113/575 0.09 6/113/575 0.08 0.95 0.68 - 1.32 0.75
16 68117197 NFAT5 rs4783720 [C/T] 22/184/488 0.16 22/184/488 0.15 1.10 0.85 - 1.43 0.47
16 68200854 NFAT5 rs17297207 [G/A] 3/69/612 0.05 3/69/612 0.07 0.66 0.44 - 0.98 0.04
16 68203623 NFAT5 rs11639947 [T/C] 22/183/467 0.17 22/183/467 0.21 0.80 0.63 - 1.02 0.07
16 68281721 NFAT5 rs1064825 [A/G] 0/74/619 0.05 0/74/619 0.06 0.84 0.55 - 1.28 0.42
16 68290961 NFAT5 rs7359336 [G/A] 128/329/227 0.43 128/329/227 0.41 1.04 0.86 - 1.26 0.69
17 42163544 WNT3 rs35937770 [A/G] 83/321/283 0.35 83/321/283 0.35 0.99 0.81 - 1.21 0.90
17 42188384 WNT3 rs35732828 [A/C] 19/200/466 0.17 19/200/466 0.17 1.05 0.81 - 1.35 0.71
17 42209035 WNT3 rs199520 [G/A] 38/237/419 0.23 38/237/419 0.22 1.04 0.83 - 1.3 0.75
17 42221887 WNT3 rs199496 [A/G] 5/117/569 0.09 5/117/569 0.07 1.11 0.78 - 1.58 0.56
17 42221965 WNT3 rs11658976 [G/A] 129/338/227 0.43 129/338/227 0.42 1.03 0.85 - 1.25 0.74
17 42223260 WNT3 rs11655598 [G/C] 46/249/387 0.25 46/249/387 0.29 0.94 0.76 - 1.16 0.57
17 42223353 WNT3 rs12452064 [A/G] 147/322/211 0.45 147/322/211 0.43 1.08 0.9 - 1.3 0.42
17 42224733 WNT3 rs10432043 [T/C] 86/301/284 0.35 86/301/284 0.33 1.07 0.88 - 1.31 0.50
17 42234514 WNT3 rs7207916 [A/G] 113/313/267 0.39 113/313/267 0.43 0.93 0.77 - 1.12 0.43
17 42243374 WNT3 rs11079737 [A/G] 54/268/338 0.28 54/268/338 0.27 1.12 0.91 - 1.38 0.30
17 42259048 WNT3 rs11079738 [G/A] 143/362/188 0.47 143/362/188 0.47 1.02 0.84 - 1.23 0.88
17 42261948 WNT3 rs8069437 [T/C] 35/225/433 0.21 35/225/433 0.23 0.85 0.68 - 1.07 0.16
19 51775092 CALM3 rs8103534 [C/T] 63/298/333 0.31 63/298/333 0.31 0.96 0.78 - 1.18 0.67
19 51781925 CALM3 rs4274528 [T/C] 7/144/542 0.11 7/144/542 0.12 1.17 0.87 - 1.57 0.31
19 51790267 CALM3 rs7260181 [C/T] 146/355/193 0.47 146/355/193 0.46 1.08 0.89 - 1.31 0.43
19 51798474 CALM3 rs4380146 [G/T] 69/284/327 0.31 69/284/327 0.32 1.03 0.84 - 1.26 0.76
19 51800325 CALM3 rs11671131 [C/T] 12/167/513 0.14 12/167/513 0.14 0.87 0.67 - 1.14 0.32
19 51804580 CALM3 rs710889 [A/G] 94/315/285 0.36 94/315/285 0.36 0.93 0.76 - 1.13 0.47
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duration of type 1 diabetes, and average HbA1c (Continued)
19 51804978 CALM3 rs10405893 [A/G] 5/153/535 0.12 5/153/535 0.11 1.25 0.92 - 1.69 0.16
19 51811750 CALM3 rs11083840 [G/T] 118/341/235 0.42 118/341/235 0.44 0.91 0.75 - 1.1 0.32
19 51811873 CALM3 rs11083841 [G/A] 26/181/457 0.18 26/181/457 0.16 1.15 0.9 - 1.47 0.26
aChr = Chromosome.
bOR = Odds Ratio.
cC.I. = 95% Confidence Interval.
dP-value, not corrected for multiple testing.
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with DN. Multivariate regression analyses of common
haplotypic structure also failed to reveal any associations
that remained significant after correction for multiple tes-
ting. All possible combinations of pair-wise SNP-SNP in-
teractions were tested as an interaction term in a logistic
regression model. Due to the large number of tests, and
the unsuitability of permutations as a correction for mul-
tiple testing in interaction analyses, the false discovery rateTable 4 Most significant results from logistic regression
analyses
a. Single SNP analysis for diabetic nephropathy
Gene SNP aOR bC.I. cP
GSK3B rs17810235 1.23 1.03 - 1.45 0.022
NFAT5 rs11639947 0.79 0.64 - 0.97 0.023
AXIN1 rs11646942 0.82 0.68 - 0.97 0.026
DAAM1 rs17095819 1.27 1.01 - 1.59 0.045
DKK2 rs17510191 1.23 1.01 - 1.49 0.047
b. Adjusted logistic regression analysis for diabetic nephropathy
GSK3B rs17810235 1.33 1.09 - 1.64 0.006
DAAM1 rs1253192 0.65 0.46 - 0.93 0.018
GSK3B rs17471 0.67 0.47 - 0.95 0.025
GSK3B rs334543 0.79 0.65 - 0.97 0.025
DAAM1 rs1252906 0.75 0.58 - 0.97 0.027
NFAT5 rs17297207 0.66 0.44 - 0.98 0.040
c. Adjusted logistic regression analysis for end-stage renal disease
WNT3 rs11079737 1.50 1.13 - 1.98 0.005
DAAM1 rs1253192 0.43 0.23 - 0.81 0.009
DAAM1 rs941882 1.45 1.08 - 1.94 0.013
CALM3 rs8103534 0.68 0.50 - 0.92 0.013
DKK2 rs6827902 1.47 1.08 - 1.99 0.015
DAAM1 rs1252906 0.60 0.40 - 0.91 0.015
WNT3 rs11079738 1.33 1.02 - 1.74 0.035
DAAM1 rs7155987 1.43 1.02 - 2.02 0.040
DAAM1 rs17834014 1.61 1.01 - 2.55 0.045
WNT6 rs940469 0.68 0.47 - 0.99 0.046
aOR: Odds Ratio.
bC.I.: 95% Confidence Intervals.
cP: value adjusted for collection centre, gender, duration of type 1 diabetes,
and average HbA1c as covariates; not corrected for multiple testing.method was used, although no associations remained sig-
nificant after correction.
There are a number of inherent limitations associated
with using a restricted number of SNPs across a chosen
set of genes [28]: (1) identification of association does
not necessarily equate to functional significance given
the concept of LD. (2) assessing one or two SNPs per
gene may provide inadequate representation of the ge-
netic architecture at that locus. (3) patterns of LD can
vary significantly within and between different popu-
lations and therefore a significant association in one
population may not necessarily translate across all popu-
lations. In addition, common genetic loci are likely to
explain only a proportion of the variation contributing
to the phenotype under consideration. Evidence in sup-
port of rare variants with potentially large individual ef-
fect size is currently under investigation in DN. Since
our study focused only on common variants, untyped,
highly penetrant rare variants in these genes could also
contribute to DN. The size of our study was such that it
had 90% power to detect variants with odds ratios of
1.69, 1.50, 1.44, and 1.42 and MAF of 10%, 20%, 30%,
and 40%, respectively. Sample sizes of the magnitude re-
quired to detect variants present in the population with
a lower frequency or with a smaller effect size were not
available for analysis and would require international,
multicentre collaborative efforts. Future amalgamation
of independent cohorts with similar DN phenotypes will
enable a more robust evaluation of such loci. In addition,
other factors such as copy number variation or indeed
epigenetic mechanisms (e.g. DNA methylation, histone
modification and microRNAs) may also modify geneTable 5 Interaction analyses with adjustment for
covariates
Gene1 SNP1 Gene2 SNP2 P aP
AXIN1 rs395901 AXIN1 rs1805105 8.40E-05 0.39
WNT6 rs690877 WNT3 rs199496 0.00043 0.58
DAAM1 rs17834014 WNT3 rs199496 0.00049 0.70
DKK2 rs398093 DAAM1 rs17834014 0.00072 0.73
GSK3B rs11917714 DKK2 rs17510191 0.00096 0.73
aCorrected for multiple testing by False Discovery Rate.
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ways and modulating disease risk accordingly.
Conclusion
There was no association observed between DN and either
common variants or haplotypes among any of the genes
associated with the WNT pathway. It is unlikely that com-
mon variants located within WNT pathway genes have a
major role in the underlying genetics of DN. Further
investigation of rare variants, copy number variants or epi-
genetic mechanisms, in WNT pathway members may
identify potential risk factors that contribute to the genetic
susceptibility of DN, in addition to identifying potential
therapeutic targets for this disease.
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